MK-1293 Insulin Glargine is a Safe and Effective Treatment Option for Type 2 Diabetes
Injection site reactions reported in 1.9% of participants in the MK-1293 group, including pain and discomfort.
In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 ...
Investigators examined the safety and efficacy of empagliflozin 10mg and linagliptin 5 mg in patients uncontrolled on linagliptin.
The correlation between the fraction of outpatient diabetes medications reconciled over a six-month period and the composite primary outcome over the subsequent six months was assessed.